Alnylam reiterates 2026 TTR sales guidance of $4.4B-$4.7B while expanding TRITON-CM enrollment to about 1,750
Source: SeekingAlpha
2026-04-30 12:52:50 ET
More on Alnylam Pharmaceuticals
- Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
- Alnylam Pharmaceuticals: Cutting-Edge Pharma Stock Still Feels A Little Overvalued
- Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise - Slideshow
- Alnylam Pharmaceuticals Non-GAAP EPS of $1.99 beats by $0.52, revenue of $1.17B beats by $50M
- Alnylam Pharmaceuticals Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Alnylam reiterates 2026 TTR sales guidance of $4.4B-$4.7B while expanding TRITON-CM enrollment to about 1,750
Alnylam Pharmaceuticals Inc.
NASDAQ: ALNY
ALNY Trading
1.21% G/L:
$289.93 Last:
247,711 Volume:
$284.48 Open:
ALNY Latest News
June 03, 2026 04:45:00 pm
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
ALNY Stock Data
$42,146,950,218
131,611,785
0.16%
379
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
